Compare MAX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAX | MLYS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 3.1B |
| IPO Year | 2020 | 2023 |
| Metric | MAX | MLYS |
|---|---|---|
| Price | $12.88 | $37.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $17.00 | ★ $47.33 |
| AVG Volume (30 Days) | 483.3K | ★ 1.6M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,093,000.00 | N/A |
| Revenue This Year | $30.80 | N/A |
| Revenue Next Year | $9.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 64.86 | N/A |
| 52 Week Low | $7.33 | $8.24 |
| 52 Week High | $13.92 | $47.65 |
| Indicator | MAX | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 43.48 |
| Support Level | $12.60 | $36.01 |
| Resistance Level | $13.21 | $39.15 |
| Average True Range (ATR) | 0.52 | 1.81 |
| MACD | -0.07 | -0.16 |
| Stochastic Oscillator | 28.15 | 31.53 |
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.